Related Experiment Video

Updated: Jan 6, 2026

Mitral Valve Prolapse III: Nursing Management
01:19

Mitral Valve Prolapse III: Nursing Management

Published on: June 19, 2025

252

Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome

Boris Bigalke1, Stephan Lindemann, Raila Ehlers

  • 1Medizinische Klinik III, Eberhard Karls-Universität Tübingen, Otfried-Müller-Str. 10, D-72076 Tübingen, Germany.

European Heart Journal
|August 23, 2006
PubMed

Insights

Elevated platelet glycoprotein VI (GPVI) levels indicate a higher risk of acute coronary syndrome (ACS) in patients with coronary artery disease (CAD). This finding may help identify at-risk patients before symptoms appear.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Thrombosis Research

Background:

  • Platelet glycoprotein VI (GPVI) is a key receptor in arterial thrombosis.
  • Understanding GPVI's role in coronary artery disease (CAD) is crucial for risk stratification.

Purpose of the Study:

  • To investigate platelet surface expression of GPVI in patients with symptomatic CAD.
  • To determine the association between GPVI levels and acute coronary events.

Main Methods:

  • Observational study of 367 patients with symptomatic CAD undergoing coronary angiography.
  • Flow cytometry used to measure platelet surface expression of GPVI, CD62P, and CD42b.
  • Logistic regression analysis to assess the association of GPVI with ACS, independent of necrosis markers.

Main Results:

  • Patients with acute coronary syndrome (ACS) exhibited significantly higher GPVI expression compared to stable angina pectoris (SAP) patients.
  • GPVI expression strongly correlated with CD62P, another platelet activation marker.
  • Elevated GPVI on admission was independently associated with ACS.

Conclusions:

  • Increased platelet GPVI surface expression is linked to ACS and predicts imminent acute coronary events.
  • GPVI serves as a potential biomarker for identifying patients at high risk for myocardial ischemia.
  • Measuring GPVI may aid in early risk assessment for cardiovascular events.
Abstract

More Related Videos

Cancer Vaccines01:30

Cancer Vaccines

917
Development of Immunocompetence01:22

Development of Immunocompetence

759

Related Concept Videos

Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
759
Vaccinations01:51

Vaccinations

Overview
51.1K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K